Back to trial

NCT04756765

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Version 0 to 1 · Stanford University

Patch inspector

Version 0 to 1

3 operations 2 path groups ctgov_internal_history
ClinicalTrials.gov
Severity is deterministic uncalibrated triage metadata, not validated review priority. Operation-level severity is inferred from deterministic path rules. Rule matches shown per operation are approximate previews (they skip the pipeline's suppression passes); the authoritative classification is the stored event record.
Plain-language summary

Manual review pending.

Rules fired
secondary_outcome_any_change
Value signals

None recorded.

Provenance
Source
ctgov_internal_history
Fetched
2026-06-18 19:13:21+00
Raw hash
2e083f8629b09d85c2fa14d5eb402dc777f1b025ec8a14f048009f16852d724c
Payload
Source URL
Secondary outcomes Additional endpoints and outcome descriptions. Triage: High 1 ops
replace /protocolSection/outcomesModule/secondaryOutcomes/3/measure
Triage: High
Secondary Outcome Change Operation 3
Matched rules
  • secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.
Before
Treatment-related Adverse Events ≥ Grade 3
After
Number of participants with Treatment-related Adverse Events ≥ Grade 3
Other registry fields Changes outside the current high-signal rule families. Triage: Uncategorized 2 ops
replace /protocolSection/statusModule/lastUpdateSubmitDate
Triage: Uncategorized
Uncategorized Operation 1
Before
2021-02-11
After
2021-02-25
replace /protocolSection/statusModule/lastUpdatePostDateStruct/date
Triage: Uncategorized
Uncategorized Operation 2
Before
2021-02-16
After
2021-03-01
Raw JSON Patch 
[
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdateSubmitDate",
    "value": "2021-02-25"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
    "value": "2021-03-01"
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/secondaryOutcomes/3/measure",
    "value": "Number of participants with Treatment-related Adverse Events ≥ Grade 3"
  }
]